Skip to main content

Academy to Feds: Step Therapy is Risky Drug Policy for Ophthalmology 

We're working to thwart proposals that could cost our patients their sight by offering other ways to lower drug costs 

In a preemptive move, the Academy is urging the U.S. Department of Health and Human Services to preserve patient choice as it develops its strategy for containing Part B drug costs in Medicare. The Academy during a cost-savings discussion with the agency earlier this month expressed unease with the possible pursuit of a "step therapy"-type policy. 

In step therapy, physicians must begin patients' treatment with a lower-cost drug, before moving to a more- expensive option. We expressed to agency leaders our strong belief that step therapy — which has yet to be formally proposed — would be inappropriate in ophthalmology. 
 
The Academy's delegation to Health and Human Services was led by David B. Glasser, MD, the Academy's secretary for federal affairs, and George A. Williams, MD, the Academy's president-elect. We were disturbed to hear that the Trump administration might consider testing “step therapy” as a means for de-incentivizing the use of high-priced Part B drugs. 
 
Agency leaders pointed to the private sector's recent imposition of step therapy for retina drugs. We countered in follow-up correspondence with pointed examples of why such an approach is wholly inappropriate for ophthalmic Part B drugs. 
 
Step therapy would create a quandary for our profession's treatment of age-related macular degeneration. The Academy doesn't believe that our low-priced available treatment — Avastin — should be mandated for therapy, since it is both off-label and compounded. Also, ophthalmologists are keenly aware that some patients respond better to other drugs. The failure of a mandated treatment at the low-price "first step" could result in lost vision. 
 
Instead, the Academy suggested that Medicare raise its payment for Avastin to be more in line with what commercial payers' rates. Doing so would more equitably cover the true costs of certain drugs' administration. In addition, CMS should also waive co-payments for the lowest-cost option. 

Related Stories

Member exclusive - Locked
Step therapy has to go

Federal Watchdog to Investigate Step Therapy in Medicare Advantage Plans, at Academy’s Urging

The Academy met with the HHS Office of Inspector to continue pressing our concerns about step therapy. The meeting follows the OIG’s September 15 announcement that it will review how Medicare Advantage plans use prior authorization and step therapy for Part B drugs, a review the Academy urged.  
 

Member exclusive - Locked Fallback image

Medicare Reintroduces Mandatory Drug Pricing Models

Ophthalmologists should continue buying and billing for eye drugs the same way. If patients' out-of-pocket costs go down, the amount Medicare pays physicians will go up to match.

Member exclusive - Locked Fallback image

White House Issues Executive Order on Lowering Drug Prices

The order could tie U.S. prices to the lowest price paid by a select number of developed countries.

Latest Updates

Member exclusive - Locked
capital building side

OPHTHPAC Midterms Recap: What the Results Mean for Ophthalmology

The 2026 midterm results are nearly final, and thanks to the support of ophthalmologists nationwide, OPHTHPAC helped secure important victories for ophthalmology this election cycle: 100 of 114 OPHTHPAC-backed candidates won their general election races, with a few results still being finalized. Here is what this year’s results mean for ophthalmology.

Member exclusive - Locked
capital building side

Final Hospital Outpatient, ASC Rule: Pay Raises for Device-Intensive Procedures, But Cuts to Other Common Ophthalmic Surgeries

Hospital outpatient departments (HOPD) and ambulatory surgical centers will get a 2.3% payment increase in 2027. But the rule released Nov. 4 by the Centers for Medicare & Medicaid Services includes hidden reimbursement cuts for most ophthalmology surgeries.

Member exclusive - Locked
HHS

2027 Fee Schedule Finalizes Pay Cut to Physicians Between 1.8% and 2.3%

The final rule from the Centers for Medicare & Medicaid Services (CMS) includes a 2.31% payment cut for physicians not participating in qualifying APMs and a 1.83% pay cut for qualifying Alternative Payment Model (APM) participants.